President Donald J. Trump has announced new measures aimed at reducing the cost of in vitro fertilization (IVF) and improving access to fertility care in the United States. The administration has reached an agreement with EMD Serono, a major global producer of fertility medications, to align American drug prices with those paid by other developed countries, using the most-favored-nation (MFN) pricing model. This approach is expected to significantly lower the costs of fertility treatments for Americans.
In addition, the Food and Drug Administration (FDA) will include a lower-cost fertility drug in the first group of products eligible for the Commissioner’s National Priority Review Voucher program. This step is intended to accelerate the availability of affordable fertility medications.
President Trump also announced a new benefit option for fertility coverage. This initiative allows employers to provide fertility benefits to employees through a legal pathway similar to existing options for dental, vision, and life insurance. The administration says this could greatly expand access to IVF coverage for American workers.
President Trump stated, "President Trump promised to increase access to IVF and lower the associated costs so American families can have more babies, building on his record of supporting family formation and stability."
